Preclinical programs for antibacterial agents worldwide by mode of action 2021
In 2021, around 4.6 percent of total antibacterial preclinical programs worldwide were using immunomodulation, while around eight percent of these programs were using protein synthesis. This statistic illustrates the share of preclinical programs for antibacterial agents worldwide, by mode of action.